Organizations that applied for the CMS Bundled Payments for Care Improvement (BPCI) Advanced model are eagerly awaiting data from CMS. What will they do with it once it arrives?
Last Friday, President Trump, with the help of Health and Human Services Secretary Alex Azar, unveiled the administration’s “Blueprint to Lower Drug Prices.” As this issue was a central tenet of President Trump’s 2016 campaign platform, guidance on the administration’s approach to tackling drug prices has long been anticipated.
Prescription drugs have long been one of the greatest plagues on the country’s healthcare costs. While this issue has garnered attention for decades, the drug debate has a renewed vigor in Washington since President Trump unveiled his “Blueprint to Lower Drug Prices” last week.
The rise of the accountable care organization (ACO) model has created an unprecedented environment to support cooperation between private physicians and health systems. Not every market or institution has been driven to use these tools to address physician alignment yet.
The US healthcare delivery system has long been chided for producing a suboptimal experience and mediocre outcomes at great cost. Now customer-centric companies are seizing the opportunity to meet patient demands for improvement on both fronts.
Provider organizations can utilize this checklistto assess program structure, organizational strategy, and capacity in order to evaluate participation in voluntary Medicaid ACO models.
Several CMS programs enable organizations that rely heavily on fee for service to ease into population health.
The rising and unsustainable cost of healthcare that precipitated the ACA still persists.
CMS's final rules on the Bipartisan Budget Act of 2015 offer guidance on interpreting the legislation.
Page 1 of 11